The FDA has requested all ranitidine (Zantac) products be pulled from the market immediately. The recall includes all prescription and over-the-counter ranitidine drugs as ongoing investigations uncovered levels of N-Nitrosodimethylamine (NDMA), a probable human carcinogen, increase over time.
The FDA has requested all ranitidine (Zantac) products be pulled from the market immediately, according to a statement. The recall includes all prescription and over-the-counter ranitidine drugs as ongoing investigations uncovered levels of N-Nitrosodimethylamine (NDMA), a probable human carcinogen, increase over time.
“The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity,” the FDA stated.
Consumers are advised to stop taking any ranitidine medications they may have, as the drug is commonly indicated for heartburn. The FDA learned an independent laboratory found NDMA in ranitidine in the summer of 2019. When the FDA conducted its own testing, it found NDMA in low levels, which “would not be expected to lead to an increase in risk in cancer.”
At that time, the FDA “did not have enough scientific evidence to recommend whether individuals should continue or stop taking ranitidine medicines and continued its investigation.” However, the agency notes it “warned the public in September 2019 of the potential risks and to consider alternative OTC and prescription treatments.”
Subsequent testing found NDMA increased in ranitidine “even under normal storage conditions,” yet increases significantly in higher than normal temperatures. These tests also found that the older a ranitidine product is, the greater the level of NDMA. While low levels of NDMA are not harmful to humans, sustained higher levels may increase the risk of cancer.
“We didn’t observe unacceptable levels of NDMA in many of the samples that we tested,” said Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research. “However, since we don’t know how or for how long the product might have been stored, we decided that it should not be available to consumers and patients unless its quality can be assured.”
Due to the COVID-19 pandemic, the FDA notes consumers should not dispose of the medication at a drug take-back location, but instead follow specific disposal instructions.
If any patients took ranitidine-containing medication and experienced adverse reactions, they should report it though the agency’s MedWatch reporting program.
The agency urges patients and providers to consider taking alternative medications. “To date, the FDA’s testing has not found NDMA in famotidine (Pepcid), cimetidine (Tagamet), esomeprazole (Nexium), lansoprazole (Prevacid) or omeprazole (Prilosec)."
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More